Next Article in Journal
Biomimetic 3D Models for Investigating the Role of Monocytes and Macrophages in Atherosclerosis
Previous Article in Journal
Biomimetic Nanocarriers for Cancer Target Therapy
Open AccessReview

Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption

1
Center for Innovative Technology, Department of Chemistry, Vanderbilt University, Nashville, TN 37212, USA
2
National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK
3
Medicines Discovery Catapult, Alderley Park, Alderley Edge, Macclesfield SK10 4TG, UK
4
Vanderbilt Institute of Chemical Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt Institute for Integrative Biosystems Research and Education, Vanderbilt University, Nashville, TN 37235, USA
5
School of Electronic and Electrical Engineering, School of Medicine, Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds LS2 9JT, UK
*
Author to whom correspondence should be addressed.
Bioengineering 2020, 7(3), 112; https://doi.org/10.3390/bioengineering7030112
Received: 19 August 2020 / Revised: 9 September 2020 / Accepted: 14 September 2020 / Published: 16 September 2020
(This article belongs to the Special Issue Organs-on-Chips, Volume 2)
Organs-on-a-Chip (OOAC) is a disruptive technology with widely recognized potential to change the efficiency, effectiveness, and costs of the drug discovery process; to advance insights into human biology; to enable clinical research where human trials are not feasible. However, further development is needed for the successful adoption and acceptance of this technology. Areas for improvement include technological maturity, more robust validation of translational and predictive in vivo-like biology, and requirements of tighter quality standards for commercial viability. In this review, we reported on the consensus around existing challenges and necessary performance benchmarks that are required toward the broader adoption of OOACs in the next five years, and we defined a potential roadmap for future translational development of OOAC technology. We provided a clear snapshot of the current developmental stage of OOAC commercialization, including existing platforms, ancillary technologies, and tools required for the use of OOAC devices, and analyze their technology readiness levels. Using data gathered from OOAC developers and end-users, we identified prevalent challenges faced by the community, strategic trends and requirements driving OOAC technology development, and existing technological bottlenecks that could be outsourced or leveraged by active collaborations with academia. View Full-Text
Keywords: organ-on-a-chip; technology-led strategy; gap analysis; validation; translation; quality management; body-on-a-chip; organotypic culture models; microphysiological systems organ-on-a-chip; technology-led strategy; gap analysis; validation; translation; quality management; body-on-a-chip; organotypic culture models; microphysiological systems
Show Figures

Graphical abstract

MDPI and ACS Style

Allwardt, V.; Ainscough, A.J.; Viswanathan, P.; Sherrod, S.D.; McLean, J.A.; Haddrick, M.; Pensabene, V. Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption. Bioengineering 2020, 7, 112.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop